Etiket: Evercore
NASDAQ title CureVac shares lower again after record low: Evercore analyst sees good basis for appeal in BioNTech legal dispute
After the previous day’s record low, CureVac’s shares attempted to stabilize on Wednesday. At a time of 4.2997 euros, the vaccine manufacturer’s papers in NASDAQ trading broke away from the…
Evercore ISI analyst sees significant upside potential for US stocks
indexes in this article Despite the ugly market environment, Evercore ISI does not fear a recession Return of private investors expectedSignificant jump in the price of the S&P 500 forecast…
Evercore Analyst: "NVIDIA is possibly the most important technology company today"
shares in this article • Evercore analyst remains bullish on NVIDIA after GTC • Autonomous driving offers great opportunities for the semiconductor specialist • NVIDIA Reports Record Q4 and FY2022…